DrugJustice

Risperdal Verdicts: The Drug Worth Two Fortunes

risperdal verdicts

Risperdal verdicts and lawsuit settlements have been adding up. Look at this infographic for details on J&J's profits on mental illness.

Risperdal verdicts and lawsuit settlements have been piling up since 2012 after consumers learned that Johnson & Johnson had been marketing the drug outside of its approved use.

Of course, prescription drugs help millions of people every day. But they come with costly side effects. When manufacturers don’t disclose the worst side effects—or illegally market a drug to broaden the base of buyers—consumers get hurt. In addition, some injuries are, unfortunately, irreparable.

Take a look at our infographic for the straight facts as well as the numbers, which includes data straight from Johnson & Johnson’s financial reports. Notably, this infographic reveals the fortune Johnson & Johnson has lost—and also made—on Americans’ mental health struggles.

Taken directly from the above infographic:

Risperdal, a drug first made to help patients fight schizophrenia, subsequently made a fortune around the globe. But lawsuits claim that Johnson & Johnson’s drug arm called Janssen Pharmaceutical illegally marketed the drug for underage patients with a wide spectrum of illnesses for which it had not been properly tested. Since then, several Risperdal verdicts have been ruled in favor of plaintiffs.

Here’s the fortune Risperdal has made, as well as the fortune it has lost from litigation.

Total Risperdal Verdicts Against Johnson & Johnson During 2012-2016

The following data represents cases claiming injuries related to Risperdal. Some of these cases are brought by states, while others come from families or individuals. These cases all claim that J&J used false, misrepresentative, or other illegal marketing tactics in order to sell more Risperdal.

Despite Lawsuits, Risperdal Annual Profits Keep Rising

Now you have an idea of how Risperdal lawsuits fared during the four-year period from 2012 and 2016. Next, let’s take a look at the available financial data provided in Johnson & Johnson’s Investor Report for each year between 2003 and 2014 to see why the company continues to manufacture a drug at the center of so much litigation.

2003$2.512B
2004$3.05B
2005$3.552B
2006$4.183B
2007$2.2B
2008$1.309B
2009$1.425B
2010$1.5B
2011$1.583B
2012$1.425B
2013$1.318B
2014$1.19B

If you or someone you loved has suffered severe side effects, including gynecomastia, due to Risperdal, you may qualify to file a Risperdal lawsuit.

Sources, which we accessed from Feb 25 to 26, 2016:

Exit mobile version